Vescica iperattiva: terapie farmacologiche a confronto

Objective: to evaluate the effectiveness and adherence to therapy of patients with Over Active Bladder (OAB) referring to Urodynamic Unit of Obstetric and Gynecologic Clinic of the University of Sassari.Materials and methods: from January 2012 to December 2014, 181 women with diagnosis of OAB or mixed Urinary Incontinence (UI) and urgency underwent pharmacological therapy (Fesoterodine fumarate: Toviaz; solifenacina succinate: Vesiker; Mirabegron: Betmiga; single therapy versus association with local estriol and pelvic floor rehabilitation). The patients underwent telephonic interview to evaluate adherence to therapy, treatment efficacy, adverse events and improving of quality of life.Results: 24.31% of patients not responded to the call (44/181) and 6.08% (11/181) refused to take part in the study. 126 patients agreed to participate: 34.13% (43/126) didn't start the treatment or discontinued it prematurely. Of these, 26% refused the treatment for economic reasons; 21%, all receiving antimuscarinic (Toviaz), stopped for side effects, 44% for comorbidities that controindicated therapy, 9% had no benefit. The patients who received the treatment reported a reduction in symptoms and improvement of quality of life in 70% of cases. Women using local estrogen therapy and Toviaz reported the greatest benefits.Conclusions: the data collected demonstrated the effectiveness of pharmacological treatment in the OAB, and greater tolerance of Mirabegron compared to antimuscarinics. We recorded a good adherence to prescribed therapy that was interrupted mainly for the presence of comorbidities and for the cost of therapy. It would be useful to confirm the data with studies with larger sample size.